Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Merck-and-CoInc stock in Canada | $71.68

Own Merck-and-CoInc shares in just a few minutes.

Merck & Co. Inc
- $0.29 ( - 0.40%)

Merck-and-CoInc is a drug manufacturers-general business based in the US. Merck-and-CoInc stocks (MRK.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $71.97 – a decrease of 2.41% over the previous week. Merck-and-CoInc employs 73,000 staff and has a trailing 12-month revenue of around $50.4 billion.

How to buy Merck-and-CoInc stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: MRK in this case.
  5. Research Merck-and-CoInc stocks. The platform should provide the latest information available.
  6. Buy your Merck-and-CoInc stocks. It's that simple.

Is it a good time to buy Merck-and-CoInc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Merck-and-CoInc's stock price?

Since the stock market crash in March caused by coronavirus, Merck-and-CoInc's stock price has had significant negative movement.

Its last market close was $71.68, which is 12.95% down on its pre-crash value of $82.34 and 9.85% up on the lowest point reached during the March crash when the stocks fell as low as $65.25.

If you had bought $1,000 worth of Merck-and-CoInc stocks at the start of February 2020, those stocks would have been worth $760.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $820.74.

Merck-and-CoInc stock price

Use our graph to track the performance of MRK stocks over time.

Merck-and-CoInc stocks at a glance

Information last updated 2021-09-17.
Latest market close$71.68
52-week range$66.6082 - $79.5043
50-day moving average $76.0326
200-day moving average $74.8557
Wall St. target price$93.21
PE ratio 32.4431
Dividend yield $2.52 (3.5%)
Earnings per share (TTM) $2.196

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Merck-and-CoInc price performance over time

Historical closes compared with the last close of $71.68

1 week (2021-09-09) -2.90%
1 month (2021-08-19) -8.64%
3 months (2021-06-18) -6.44%
6 months (2021-03-19) -7.52%
1 year (2020-09-18) -16.40%
2 years (2019-09-18) -13.59%
3 years (2018-09-18) 1.87%
5 years (2016-09-16) 15.18%

Is Merck-and-CoInc under- or over-valued?

Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-CoInc's P/E ratio

Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Merck-and-CoInc stocks trade at around 32x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.

Merck-and-CoInc's PEG ratio

Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3485. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Merck-and-CoInc's EBITDA

Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$19.9 billion.

The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.

Merck-and-CoInc financials

Revenue TTM USD$50.4 billion
Operating margin TTM 33.02%
Gross profit TTM USD$34.6 billion
Return on assets TTM 11.47%
Return on equity TTM 20.4%
Profit margin 11.06%
Book value $13.145
Market capitalisation USD$182.5 billion

TTM: trailing 12 months

How to short and sell Merck-and-CoInc stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "MRK.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 27.4 million Merck-and-CoInc stocks held short by investors – that's known as Merck-and-CoInc's "short interest". This figure is 18.3% up from 23.2 million last month.

There are a few different ways that this level of interest in shorting Merck-and-CoInc stocks can be evaluated.

Merck-and-CoInc's "short interest ratio" (SIR)

Merck-and-CoInc's "short interest ratio" (SIR) is the quantity of Merck-and-CoInc stocks currently shorted divided by the average quantity of Merck-and-CoInc stocks traded daily (recently around 8.3 million). Merck-and-CoInc's SIR currently stands at 3.32. In other words for every 100,000 Merck-and-CoInc stocks traded daily on the market, roughly 3320 stocks are currently held short.

However Merck-and-CoInc's short interest can also be evaluated against the total number of Merck-and-CoInc stocks, or, against the total number of tradable Merck-and-CoInc stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merck-and-CoInc's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Merck-and-CoInc stocks in existence, roughly 10 stocks are currently held short) or 0.0109% of the tradable stocks (for every 100,000 tradable Merck-and-CoInc stocks, roughly 11 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Merck-and-CoInc.

Find out more about how you can short Merck-and-CoInc stock.

Merck-and-CoInc's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Merck-and-CoInc's total ESG risk score

Total ESG risk: 28.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Merck-and-CoInc's environmental score

Environmental score: 3.15/100

Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Merck-and-CoInc's social score

Social score: 15.55/100

Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Merck-and-CoInc's governance score

Governance score: 12.65/100

Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Merck-and-CoInc's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Merck & Co. Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.35
Total ESG percentile 47.16
Environmental score 3.15
Environmental score percentile 4
Social score 15.55
Social score percentile 4
Governance score 12.65
Governance score percentile 4
Level of controversy 3

Merck-and-CoInc stock dividends


Dividend payout ratio: 44.01% of net profits

Recently Merck-and-CoInc has paid out, on average, around 44.01% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.61% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.52 per share.

While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.

Merck-and-CoInc's most recent dividend payout was on 7 October 2021. The latest dividend was paid out to all shareholders who bought their stocks by 14 September 2021 (the "ex-dividend date").

Have Merck-and-CoInc stocks ever split?

Merck-and-CoInc stocks were split on a 1048:1000 basis on 3 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc stocks – just the quantity. However, indirectly, the new 4.6% lower stock price could have impacted the market appetite for Merck-and-CoInc stocks which in turn could have impacted Merck-and-CoInc's stock price.

Merck-and-CoInc stock price volatility

Over the last 12 months, Merck-and-CoInc's stocks have ranged in value from as little as $66.6082 up to $79.5043. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4209. This would suggest that Merck-and-CoInc's stocks are less volatile than average (for this exchange).

Merck-and-CoInc overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site